The UK Government’s recently released “Levelling up White Paper” makes for interesting reading in the context of the life sciences sector.
In advance of a more in-depth review, here are some of the key points and my thoughts, focusing on two of the main areas of relevance to the sector: small company finance and R&D expenditure.
Cambridge UK: 07 February 2022
Bidwells LLP, widely recognized as a pioneer and the leading science & technology property adviser in the UK has become the latest Partner to join One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
London & Cambridge, United Kingdom, 3rd February 2022 / Sciad Newswire / Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, and Domainex Ltd., today announce a collaboration focused on developing small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s. Domainex, a leading integrated medicines research services partner, will provide fully integrated drug discovery services including assay biology, medicinal and computational chemistry.
CAMBRIDGE, UK (02 Feb 2022) – Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, today announced that the first close of its Series B financing has raised $42.5 million. The funds raised will be used to accelerate the development and commercialization of its eProtein™ desktop bioprinter.
Cambridge, UK, February 1, 2022 — Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors. The investment will fund the upcoming launch of ASPYRE-Lung, the company’s first commercial diagnostic assay based on its breakthrough molecular technology.
OXFORD, UK January 31, 2022 –PrecisionLife Limited, the global techbio company driving precision medicine in chronic disease with AI-led drug discovery, clinical development, and healthcare solutions, announces the first close of its Series A investment round. The financing, which is ongoing, will enable expansion and progression of its extensive and growing pipeline of commercial opportunities targeting complex chronic diseases. The company anticipates the second close of the Series A investment round in the coming months.
Edinburgh and Cambridge, UK, 24 January 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has added five new internationally renowned Advisors to expand the immunology, oncology and clinical expertise within its advisory panel. The new additions from the Netherlands, France, Switzerland, the UK and Italy are Professor Karin de Visser, Dr Carlos Gomez-Roca, Professor Daniel Speiser, Professor Klaus Okkenhaug and Dr Mario Leonardo Squadrito.
The Board of PIR International, a leading provider of executive search and interim services to the global life science industry, today announced the finalisation of an MBO with the executive team of the business, Sally Hope, Stuart Penney, and Tom Bradley, who will acquire the majority of shares from the founder, Carolyn Douthwaite.
This cell culture supplement can be used to manufacture both autologous and allogeneic cell therapies
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the launch of its Good Manufacturing Practice (GMP) grade human AB serum, a cell culture supplement to enhance the development and manufacturing of cell and gene therapies.